The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
Oncopeptides is a biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company´s lead product is approved on several markets for treatment of adult patients with multiple myeloma. The company’s shares are admitted to trading on Nasdaq Stockholm.